Antiprotozoal activity profiling of approved drugs: A starting point toward drug repositioning

Marcel Kaiser, Pascal Mäser, Leela Pavan Tadoori, Jean Robert Ioset, Reto Brun, David J. Sullivan

Research output: Contribution to journalArticlepeer-review

53 Scopus citations


Neglected tropical diseases cause significant morbidity and mortality and are a source of poverty in endemic countries. Only a few drugs are available to treat diseases such as leish-maniasis, Chagas' disease, human African trypanosomiasis and malaria. Since drug development is lengthy and expensive, a drug repurposing strategy offers an attractive fast-track approach to speed up the process. A set of 100 registered drugs with drug repositioning potential for neglected diseases was assembled and tested in vitro against four protozoan parasites associated with the aforementioned diseases. Several drugs and drug classes showed in vitro activity in those screening assays. The results are critically reviewed and discussed in the perspective of a follow-up drug repositioning strategy where R&D has to be addressed with limited resources.

Original languageEnglish (US)
Article numbere0135556
JournalPloS one
Issue number8
StatePublished - Aug 13 2015

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Antiprotozoal activity profiling of approved drugs: A starting point toward drug repositioning'. Together they form a unique fingerprint.

Cite this